To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The European response to control and manage multi- and extensively drug-resistant Neisseria gonorrhoeae
UK Health Security Agency, London, United Kingdom.
UK Health Security Agency, London, United Kingdom.
Örebro University, School of Medical Sciences. Örebro University Hospital. World Health Organization Collaborating Centre for Gonorrhoea and other STIs.
European Centre for Disease Prevention and Control, Stockholm, Sweden.
Show others and affiliations
2022 (English)In: Eurosurveillance, ISSN 1025-496X, E-ISSN 1560-7917, Vol. 27, no 18, p. 37-43Article in journal (Refereed) Published
Abstract [en]

Because cefixime and ceftriaxone resistance in Neisseria gonorrhoeae and gonorrhoea treatment failures were increasing, a response plan to control and manage multidrug-resistant N. gonorrhoeae (MDR-NG) in Europe was published in 2012. The three main areas of the plan were to: (i) strengthen surveillance of antimicrobial resistance (AMR), (ii) implement monitoring of treatment failures and (iii) establish a communication strategy to increase awareness and disseminate AMR results. Since 2012, several additional extensively drug-resistant N. gonorrhoeae (XDR-NG) strains have emerged, and strains with high-level ceftriaxone resistance spread internationally. This prompted an evaluation and review of the 2012 European Centre for Disease Prevention and Control (ECDC) response plan, revealing an overall improvement in many aspects of monitoring AMR in N. gonorrhoeae; however, treatment failure monitoring was a weakness. Accordingly, the plan was updated in 2019 to further support European Union/European Economic Area (EU/EEA) countries in controlling and managing the threat of MDR/XDR-NG in Europe through further strengthening of AMR surveillance and clinical management including treatment failure monitoring. The plan will be assessed biennially to ensure its effectiveness and its value. Along with prevention, diagnostic, treatment and epidemiological surveillance strategies, AMR surveillance is essential for effective control of gonorrhoea.

Place, publisher, year, edition, pages
European Centre for Disease Prevention and Control , 2022. Vol. 27, no 18, p. 37-43
Keywords [en]
EU/EEA, MDR-NG, XDR-NG, antimicrobial resistance, cephalosporins, gonorrhoea, surveillance, treatment failure
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-98903DOI: 10.2807/1560-7917.ES.2022.27.18.2100611ISI: 000834892300005PubMedID: 35514307Scopus ID: 2-s2.0-85129438353OAI: oai:DiVA.org:oru-98903DiVA, id: diva2:1656860
Note

Funding agency:

European Centre for Disease Prevention and Control ECDC/2013/015

Available from: 2022-05-09 Created: 2022-05-09 Last updated: 2023-07-03Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Jacobsson, SusanneUnemo, Magnus

Search in DiVA

By author/editor
Jacobsson, SusanneUnemo, Magnus
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Eurosurveillance
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 41 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf